SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
--------------
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 28, 1997
--------------
EPITOPE, INC.
(Exact name of Registrant as specified in charter)
Oregon
(State or other jurisdiction of incorporation)
1-10492
(Commission File No.)
93-0779127
(IRS Employer Identification No.)
8505 S.W. Creekside Place
Beaverton, Oregon 97008
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code:
(503) 641-6115
Item 5. Other Events.
On July 28, 1997, Epitope, Inc. (the "Company"), issued a
press release announcing two significant corporate events.
The Company intends to spin off its Agritope agricultural
biotechnology unit, subject to obtaining additional capital from investors and
strategic partners to support the unit's operation as a separate business and to
receipt of regulatory approval.
The Company will re-acquire from SmithKline Beecham plc ("SB")
all rights to the Company's patented oral fluid diagnostic technology pursuant
to termination of its Development, License and Supply Agreement with SB.
A copy of the press release is attached as an exhibit to this
report.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(a) Not applicable.
(b) Not applicable.
(c) Exhibits.
The exhibit to this report is listed in the exhibit index
following the signature page.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
EPITOPE, INC.
Dated: July 28, 1997 By /s/ W. Charles Armstrong
W. Charles Armstrong
President and Chief Executive Officer
EXHIBIT INDEX
99 Press release of Epitope, Inc., dated July 28, 1997.